Holding in Company

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that it was notified on 20 August 2026 by Robert McFadden that as of 18 August 2026 he holds 13,678,940 ordinary shares of 0.4 pence each in the Company representing 3.02% of the Company’s issued share capital, following a market purchase at 0.47 pence per share. The interest is held directly.

 

ENDS

 

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

 

 

Enquiries:

 

Physiomics plc Mike Whitlow	Email:  info@physiomics.co.uk
Strand Hanson Ltd (NOMAD and Broker) James Dance & James Bellman	Tel:  +44 (0) 20 7409 3494

 

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.